AA
WST icon

AlphaCentric Advisors’s West Pharmaceutical WST Stock Holding History

AlphaCentric Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-219
Closed -$93K – 278
2021
Q3 		$93K Sell
219
-1
-0.5% -$422 0.02% 171
2021
Q2 		$79K Buy
220
+28
+15% +$9.25K 0.02% 186
2021
Q1 		$54K Sell
192
-7
-4% -$2K 0.02% 185
2020
Q4 		$56K Buy
+199
New +$55.8K 0.02% 174

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AlphaCentric Advisors's WST Position: Q4 2021 in Review

AlphaCentric Advisors sold out of West Pharmaceutical (WST) in Q4 2021, closing a stake of 219 shares — an estimated $93K sold.

AlphaCentric Advisors first reported a position in WST in Q4 2020 and held it in 4 quarters. The position peaked at $93K in Q3 2021. 729 funds tracked by Wall St. Rank hold WST as of Q4 2021.

  • AlphaCentric Advisors reported no remaining West Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 219 West Pharmaceutical shares in Q4 2021, an estimated $93K.
  • AlphaCentric Advisors first reported a position in West Pharmaceutical in Q4 2020 and held it in 4 quarters.
  • AlphaCentric Advisors's West Pharmaceutical position peaked at $93K in Q3 2021.
  • 729 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.